The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Alexion to Host Conference Call This Morning to Discuss Company's Proposed Acquisition of Enobia Pharma Corp.

Thursday, December 29, 2011

Alexion to Host Conference Call This Morning to Discuss Company's Proposed Acquisition of Enobia Pharma Corp.06:00 EST Thursday, December 29, 2011 CHESHIRE, Conn. (Business Wire) -- As previously announced, Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) will conduct a conference call at 9:00AM Eastern Time today, December 29, to discuss the Company's proposed acquisition of Enobia Pharma Corp. To access the live call, please dial 1-888-297-0356 (U.S.) or 1-719-325-2109 (international). The conference passcode number is 5470489. Telephone replay will be available for a limited period following the call, beginning at 12:00PM Eastern Time. The replay number is 888-203-1112 (USA) or 719-457-0820 (International), confirmation code 5470489. The audio webcast can be accessed at www.alexionpharma.com. About Alexion Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 35 countries for the treatment of PNH, and in the United States and the European Union for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com. Alexion:Irving Adler, 203-271-8210Sr. Director, Corporate CommunicationsorAlexion Media Contact:Makovsky + CompanyKristie Kuhl, 212-508-9642